The drug is for the treatment of Critical Limb Ischemia
Stempeutics Research's stem-cell based drug Stempeucel has received a process patent from the United States Patent and Trademarks Office.
"The patent granted is a strong recognition for Stempeutics for its sustained excellence of scientific and clinical work," said Mr B N Manohar, chief executive of Stempeutics, in a statement.
The drug is for the treatment of Critical Limb Ischemia (CLI). It directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself.
"We believe that the Stempeucel is a game-changer offering, an advanced therapeutic treatment for millions of patient suffering with this dreadful disease," said Mr Manohar.
Stempeutics has already submitted its applications to Drug Controller General of India (DCGI) to obtain marketing authorization approval for Stempeucel.
